- socially bharat
- November 12, 2024
Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial
Darmstadt, Germany: Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0%